| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Internal Medicine (M.P., M.A.T., H.V.N., C.T.S., A.L.G., J.B.C., M.J.A.S., L.A.V.) and Physiology and Biophysics (V.A., G.V., M.C.C.G.M., A.C.B., E.M.C.), State University of Campinas; and Department of Zoology (A.P.C.-N.), Paulista State University, Campus Rio ClaroState University of Sao Paulo, 13083-970 Campinas SP, Brazil
Address all correspondence and requests for reprints to: Lício A. Velloso, Departamento de Clínica Médica, FCM-UNICAMP, 13083-970 Campinas SP, Brazil. E-mail: lavelloso{at}fcm.unicamp.br.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Loss of coordinated control of food ingestion and energy expenditure is thought to be a central issue in the development of obesity, one of the most prevalent and life-threatening diseases of the modern world (9). A recent study has shown that defects in signaling of several hypothalamic neurotransmitters, such as neuropeptide Y, cocaine- and amphetamine-regulated transcript, agouti-related peptide,
-MSH, pro-opiomelanocortin, melanin-concentrating hormone (MCH), and orexin (10), as well as defects of leptin and insulin signaling in hypothalamus, may lead to disturbances of feeding and weight control (11, 12).
Because, under cold exposure, high food consumption is associated with weight loss and increased thermogenesis, we decided to use cDNA-macroarray analyses to identify candidate hypothalamic proteins that are modulated in response to cold and, therefore, evaluate their participation in the processes that integrate energy expenditure and food consumption.
Among 1176 different mRNA specificities analyzed, cold exposure induced the modulation of expression of 56 different mRNA specificities in rat hypothalamus. Initial interest was drawn over the neurotransmitter MCH, a 19-amino-acid peptide, expressed mostly in neurons of the lateral hypothalamus (LH) and known to induce hyperphagia and weight gain, if intracerebroventricularly (ICV)-injected, in experimental animals (13, 14). Moreover, the lack of MCH signaling, by knocking out the expression of its receptor in the central nervous system, leads to moderate hypophagia and leanness (15, 16). Based on these facts, we decided to evaluate the role of MCH hyperexpression in the hypothalamus of cold-exposed rats by blocking its protein synthesis using a phosphorthioate-modified MCH-specific antisense oligonucleotide.
| Materials and Methods |
|---|
|
|
|---|
-33P]dATP was from Amersham Corp.
Experimental animals and cold-exposure protocols
Male Wistar rats (5670 d old/200260 g) from the University of Campinas Central Animal Breeding Center were used in the experiments. The Universitys Ethical Committee approved the protocols. The animals were maintained on a 12-h artificial light, 12-h dark cycle and kept in individual cages supplied with standard rodent chow and water ad libitum. After an acclimatizing period (3 d), rats were transferred to metabolic cages and randomly assigned to two treatment conditions: control and cold-exposed [temperature (T) +4 C]. Rats of the control group were continuously maintained at 23 ± 1 C, whereas rats of the T +4 C group were housed at 4 ± 1 C. Protocols lasting 2 h and 2, 4, 8, and 16 d were employed. For hormone and biochemical determinations, samples were collected from eight rats of each group, and analyses were run in duplicates. For cDNA preparation for macroarray analysis, mRNA extracted from the hypothalami of three rats of each group was pooled, reverse transcribed, and used in the hybridization protocol; three pools from each condition were evaluated. For the remaining experiments, four rats of each group were analyzed, and the experiments were run in duplicates or triplicates.
ICV cannulation and ICV oligonucleotide injection
Adult male Wistar rats were stereotaxically instrumented under sodium amobarbital (15 mg/kg body weight) anesthesia with chronic unilateral 26-gauge stainless steel indwelling guide cannulas, aseptically placed into the lateral ventricle (0.2 mm posterior, 1.5 mm lateral, and 4.2 mm ventral to bregma) as previously described (13). After a 1-wk recovery period, all rats were kept in individual cages and exposed either to 23 ± 1 C (control) or to 4 ± 1 C (T +4 C) during 4 d. Sense and antisense MCH oligonucleotides were diluted in TE buffer (10 mM Tris-HCl, 1 mM EDTA) and injected once a day at 1000 h, with a total vol of 2.0 µl per dose (2.0 nmol/µl), 24, 48, and 72 h after the onset of the experimental period. Rats were randomly assigned to six different treatment conditions: control without oligonucleotide treatment (control WO); cold exposed without oligonucleotide treatment (T +4 C WO); control with sense oligonucleotide treatment (control S); cold exposed with sense oligonucleotide treatment (T +4 C S); control with antisense oligonucleotide treatment (control AS); cold exposed with antisense oligonucleotide treatment (T +4 C AS).
Biochemical, hormonal, and metabolic characterization of experimental animals
During the animal model characterization, the measurements of food intake, rectal temperature, and body weight were obtained at 1400 h daily from experimental d 1 to experimental d 8, and on experimental d 16. During ICV injection protocol, the measurements were performed daily during the whole experimental period. Rectal temperature was measured with a Thermistor digital (HI-8753) high-precision thermometer (Hanna Instruments, Inc., Woonsocket, RI) inserted 1.5 cm from the anus. Plasma glucose was determined by the glucose oxidase method (17), RIA was employed to measure serum insulin according to a previous description (18), leptin concentrations were determined using a commercially available ELISA kit (Crystal Chem. Inc., Chicago, IL), and corticosterone and TSH were detected by commercially available RIA kits (Amersham Biosciences, Biotrak, Aylesbury, UK). Glycogen was measured, according to a previously described method (19), in liver and gastrocnemius muscle fragments, at experimental d 8 (during the animal model characterization) and at experimental d 4 (during ICV oligonucleotide treatment). Body carcass composition was determined as previously described (20).
Metabolic measurements
Rates of oxygen consumption (VO2) and carbon dioxide production (VCO2) were measured by open-flow respirometry, with a set-up modified from a previously published method (21). After 14 h fasting, rats were placed individually into polyvinyl chloride respirometric chambers, which were then installed into a temperature-controlled cabinet (±0.1 C). Air was drawn over ascarite and drierite scrubbers to remove CO2 and H2O to a manifold, which divided the flow into four airstreams. Each stream was regulated at 15002500 ml/min, depending on the experimental temperature. The constancy of the flow was periodically checked with a Cole-Palmer (Vernon Hills, IL) flow meter, and less then 1% drift during the experiments was detected. Each stream fed the inlet port of each of the four respirometric chambers, one of which contained no experimental animal and was used as a baseline reference. Air leaving each respirometric chamber was directed into a computer-controlled multiplexer, where four solenoid vales selected which flow would be directed to a computer-controlled mass-flow meter (model 840; Sierra Instruments, Inc., Monterey, CA). The mass-flow meter was adjusted to deliver a constant flow of 300 ml/min of air, sequentially through water scrubbers, to the measurement cell of a CA-2A CO2 analyzer (Sable Systems International, Las Vegas, NV), again through water and gas scrubbers, and finally to the measurement cell of a FC-1B O2 analyzer (Sable). Each chamber with a rat was sampled for 20 min. Thus, a complete set of recording lasted for 80 min, and this sequence was repeated six times during the evaluation period. Experiments started at 1000 h and finished at 1800 h. VO2 and VCO2 were calculated by the Datacan program, based in the equations of Withers (22) and were expressed as milliliters per hour per gram. Animals were weighed immediately before and after the metabolic measurements, and the average of these two measurements was used as the body mass value for these calculations. The respiratory quotient (RQ) was calculated as: VCO2/VO2.
cDNA arrays analysis and RT-PCR
RNA preparation.
Control and cold-exposed rat hypothalamus were excised and rapidly frozen in liquid nitrogen. Total RNA was extracted using Trizol reagent, according to the manufacturers recommendations. Total RNA was quantified by spectrophotometry at A260 nm, and its integrity was determined from the A260:A280 nm ratio. After 24 h, isolated total RNA was rendered genomic-DNA-free by digestion with ribonuclease-free deoxyribonuclease (RQ1; Promega, Madison, WI).
Array hybridization.
The recommended protocol was followed in all steps. Briefly, 1 µg poly(A)+ RNA was converted into 33P-labeled first-strand cDNA by Moloney murine leukemia virus reverse transcriptase. Unincorporated 33P-labeled nucleotides were removed by chromatography using a NucleoSpin Extraction Spin Column (CLONTECH, Palo Alto, CA). Purified cDNA probes were hybridized to the Atlas membranes. Hybridization occurred overnight at 68 C. After washing, membranes were sealed in hybridization bags and exposed to imaging plates for 1 d. After exposure, the imaging plates were scanned using a BAS-1500 (Fujifilm, Fuji, Japan), and hybridization signals were counted. Hybridization signals of each gene were normalized by a positive control (signals of the housekeeping gene), and gene expression was compared between the preconditioning and control groups. Genes exhibiting differential expression in the preconditioning group were selected only if the hybridization signals were either increased or decreased by at least 2-fold, compared with those of the control group.
Semiquantitative RT-PCR.
Seven micrograms of total RNA, obtained from hypothalamus of rats exposed, or not, to cold during 4 d, were reverse-transcribed with SuperScript reverse transcriptase (200 U/µl) using oligo(deoxythymidine) (50 mM) in a 30-µl reaction vol [5x reverse transcription (RT) buffer, 10 mM deoxynucleotide triphosphate, and 40 U/µl ribonuclease-free inhibitor]. The RTs involved a 50-min incubation at 42 C and a 15-min incubation at 70 C. After RT, 0.75 µl of the RT product was used in each PCR to a final vol of 50 µl (10x PCR buffer, 1.0 mM deoxynucleotide triphosphate, 50 mM MgCl2, Taq polymerase, and sense and antisense primers for MCH and ß-actin). The expression of mRNA was determined by PCR, using the primers described above, and amplified a 323-bp DNA fragment of MCH and a 533-bp DNA fragment of ß-actin. Triplicate reactions were done using an initial incubation at 94 C for 5 min, denaturation at 94 C for 1 min, followed by annealing at 50 and 57 C (MCH and ß-actin, respectively) for 50 sec, extension at 72 C for 1 min, and final extension at 72 C for 7 min. After titration between 16 and 32 cycles, 22 cycles was selected for quantification of MCH and ß-actin. These PCR conditions were therefore used in all subsequent experiments. All PCR experiments included a control tube with no RT step. PCR-amplified products were run on 2% Tris/acetic acid/EDTA agarose gels, and the DNA was visualized by ethidium bromide staining. The size of the products was determined using a 1-kb plus DNA ladder (Life Technologies) as standard size markers. Images of the bands were captured using a TFX 35M UV transluminator (Life Technologies), and band intensity was quantified by digital densitometry (Scion Image software, Scion Corp., Frederick, MD). Results are expressed as the ratio of MCH/ß-actin ± SEM, in arbitrary scanning units.
Protein analyses by Western blot and dot-blot
UCP1 was measured in brown adipose tissue (BAT) of rats submitted to ICV cannulation and treated according to the following protocols: control WO; T +4 C WO; control S; T +4 C S; control AS; and T +4 C AS. Western blot analyses followed previously described methods (23, 24) using a specific anti-UCP1 polyclonal antibody. The intensity of protein bands corresponding to UCP1 was quantified by digital densitometry (Scion Image software) of the developed autoradiographs. MCH was measured in hypothalamus of rats exposed, or not, to cold (without previous stereotaxic instrumentation), or in rats submitted to ICV cannulation and treated according to the same protocols as stated above for UCP1 measurements. For the detection of MCH in hypothalamic protein extracts, a preparatory step of protein purification by filtration was performed using a Microcon YN-3 device. A method for specific peptide detection by dot-blot, previously described (25), was used. The signal obtained was measured by digital densitometry (Scion Image software) of the developed autoradiographs. Highly purified MCH was used as control.
Determination of hypothalamic MCH by RIA
For hypothalamic MCH determination by RIA, hypothalami of rats of each experimental group were homogenized in ice-cold buffer containing 100 mM Tris (pH 7.6), 1% (vol/vol) Triton X-100, 150 mM NaCl, 0.1 mg/ml aprotinin, 2 mM phenylmethylsulfonylfluoride, 10 mM Na3VO4, 100 mM NaF, 10 mM Na4P2O7, and 4 mM EDTA, using a PTA 20S polytron generator (Brinkmann Instruments, Westbury, NY). Homogenates were then centrifuged at 12,000 x g for 20 min at +4 C. Protein concentration of supernatants was determined by the Bradford method (26). Samples containing 2.0 mg/ml protein were evaluated for the concentration of MCH using a RIA kit, following the recommendations of the manufacturer (Phoenix Pharmaceuticals, Inc.) (27).
Data presentation and statistical analysis
All numerical results are expressed as the mean ± SEM of the indicated number of experiments. The results of blots are presented as direct comparisons of bands or dots in autoradiographs and quantified by densitometry using the Scion Image software. Data were analyzed by the two-tailed unpaired Students t test or by repeat-measures ANOVA (one-way or two-way ANOVA) followed by post hoc analysis of significance (Bonferroni test) when appropriate, comparing experimental and control groups. The level of significance was set at P < 0.05.
| Results |
|---|
|
|
|---|
|
|
|
|
100%, P < 0.05). Moreover, an unexpectedly significant fall of body weight (P < 0.05) was also observed in rats maintained at room temperature that received MCH antisense oligonucleotide (Fig. 2D
|
400%, P < 0.05) and muscle (
50%, not significant) glycogen contents; however, if the rats exposed to cold were treated with antisense oligonucleotide, lower levels of liver (
120%, P < 0.05, vs. T +4 C WO) and muscle (
20%, not significant) glycogen increments were detected. On the other hand, relative body fat was significantly reduced in rats exposed to cold; if cold-exposed rats were treated with antisense MCH oligonucleotide, higher amounts of relative body fat were encountered (P < 0.05, vs. T +4 C WO). Finally, lean body mass was unaffected by cold exposure; however, under MCH blockade, cold-exposed animals consumed significantly higher amounts of relative lean body mass, which differed from that observed in cold-exposed non-antisense-MCH-oligonucleotide-treated rats (P < 0.05).
|
Effects of MCH protein synthesis blockade on BAT UCP1 expression
Prolonged survival of homeothermic animals exposed to cold depends on efficient means of maintaining a stable body temperature. In rodents, much of this function is exerted by BAT located mostly in interscapular space and perirenal area. Heat production in BAT is, at least in part, driven by a leak of the mitochondria electron transport chain, and UCP1 is directly involved in this process (30). To investigate the participation of MCH on cold-induced UCP1 induction, Western blot analyses were employed to measure interscapular UCP1 expression in cold-exposed MCH-blocked rats and compare them with respective controls. As shown in Fig. 4
, cold exposure induced an increase of approximately 30% (P < 0.05) in UCP1 expression in BAT. Blockade of hypothalamic MCH promoted a further significant increase in UCP1 expression in cold-exposed rats (P < 0.05 vs. cold exposed with no oligonucleotide treatment); and, in fact, even in non-cold-exposed rats, the treatment with MCH antisense oligonucleotide induced a nonsignificant increase (P = 0.058) in UCP1 expression in BAT, as compared with control. The same period of MCH blockade promoted a significant increase in relative [BAT weight (g)/body weight (g)] interscapular BAT weight (0.099 ± 0.004 vs. 0.083 ± 0.003% for cold-exposed, antisense MCH-treated and cold-exposed, non-oligonucleotide-treated rats, respectively).
|
| Discussion |
|---|
|
|
|---|
Since the seminal work of Qu and collaborators (12), most studies have emphasized the attribute of MCH to increase food consumption in experimental animals (10, 32, 33). Therefore, it was surprising that the partial blockade of MCH provided by ICV oligonucleotide treatment led to no significant modulation of food ingestion in cold-exposed and in control rats. Taking a closer look at the data available in the literature concerning MCH effects on feeding behavior, it becomes clear that this is not a straightforward matter. It seems that acute ICV injection of MCH promotes significant increase of food intake (12, 13, 34), whereas chronic ICV infusion does not lead to significant increase of caloric intake if rats are maintained under regular chow, but does so if they are treated with a high-fat diet (35, 36). The blockade of hypothalamic MCH activity by ICV infusion of a selective MCH1-R antagonist promotes evident acute effects on feeding inhibition and only moderate effects after chronic treatment (37). The recombinant hyperexpression of MCH also leads to increased food ingestion and obesity, but the magnitude of feeding augment is not as exuberant as in acutely MCH-treated animals (10). Finally, targeted-disruption of MCH1-R results in hyperphagia and resistance to diet-induced obesity (7, 15). Thus, it seems that the orexigenic effects of MCH in hypothalamus are dependent on the duration of stimulus and on receptor subtype, and that some of the approaches used to modulate MCH action produce substantial changes of body weight that are not accompanied by similar regulation of food intake.
Body temperature was another parameter evaluated in the present study. Normal rats exposed to cold environment (+4 C) present an early fall in body temperature, reaching a nadir of approximately 33 C (rectal) after 26 h and returning to euthermia after 2448 h at most (28, 29). After 4 d of MCH blockade, no significant changes in rectal temperature were detected in cold-exposed and control rats. These findings are in accordance with previous pharmacological and recombinant approaches undertaken to study MCH function in hypothalamus (12, 13, 34, 37).
Different from the two previous parameters evaluated, body weight was significantly influenced by the partial blockade of MCH. As in the present study, most previously published data show that exposure of rats to +4 C leads to an initial loss of body weight, which is followed by gradual recovery. However, even after several weeks, cold-exposed rats do not reach the same rate of weight gain as their matched controls maintained at room temperature. In the present experiments, MCH-blocked, cold-exposed rats presented a significantly greater weight loss than their controls, and even non-cold-exposed rats treated with MCH antisense oligonucleotide underwent significant weight loss.
Because the blockade of MCH expression produced significantly greater weight loss than in respective controls, which was not accompanied by changes in food intake and body temperature, we decided to measure body energy stocks, oxygen consumption, carbon dioxide production, RQ, and UCP1 expression in BAT, as indirect means of estimating the flow of the energy that was lost in MCH-blocked animals, and the participation of BAT in thermogenic adaptation after cold exposure and MCH signaling interference. The data herein presented reveals that blockade of MCH reduces liver and muscle glycogen content, increases relative amounts of body fat, and decreases relative amounts of lean mass of cold-exposed rats. Moreover, in MCH-blocked rats, the amount of UCP1 in BAT, which is significantly stimulated by cold exposure, suffers a further and significant increment, which is accompanied by an increase in the relative weight of BAT. All these changes occurred in the absence of major modifications of O2 consumption, CO2 production, and RQ.
BAT is a specialized organ that actively participates in the production of heat. Hypothalamic nuclei stimulate BAT activity and UCP1 expression by sympathetic inputs. In a recent study, the origin of sympathetic connections that innervate BAT has been mapped to paraventricular nucleus, LH, prefornical area, and retrochiasmatic nucleus (38). Thus, as one of the predominant neurotransmitters expressed in the LH, MCH may participate in the control of UCP1 expression and BAT activity in certain conditions. Based on the present findings, it seems that, during cold exposure, the optimal expression of UCP1, which is required for full thermogenic activity of BAT, is dependent on increased MCH expression in hypothalamus. Once MCH expression is disrupted, the animals may loose the capacity of tight regulation of energy expenditure for heat production, and increased UCP1 may be a reflection of that.
Energy expenditure by motor activity is another possible mechanism involved in MCH-dependent body weight control. According to Marsh and colleagues (15), the disruption of MCH1-R gene produces a phenotype of leanness, motor hyperactivity, and hyperphagia. Apparently, most of the increased metabolic rate of this animal model is attributable to hyperactivity, because it was detected during the dark phase of the light-dark cycle. This observation may explain why many studies, including the present one, that attempted to characterize the role of hypothalamic MCH signaling on food intake and body weight control, encountered no straight correlation between variation in caloric intake and body weight. This may also explain why, in the present study, no significant changes in O2 consumption, CO2 production, and RQ were detected, because the rats were restrained during the measurements.
Finally, a recent study (39) provides, by indirect means, further support for a role of MCH in energy expenditure control. The treatment of rodents with the fatty acid synthase inhibitor C75 was shown to induce hypophagia accompanied by a nonproportional loss of body weight, i.e. C75-treated rats lose weight to a lesser extent than food-deprived rats, although both groups have no caloric intake. These animals express less hypothalamic neuropeptide Y and Agouti-related peptide, and more pro-opiomelanocortin and cocaine- and amphetamine-regulated transcript, than their controls. However, most important, in our opinion, is the fact that they express higher levels of hypothalamic MCH. Taken together with the data herein presented, it seems that, during some situations that provoke catabolism, the levels of hypothalamic MCH are increased to provide means for minimizing energy expenditure during adversity.
In conclusion, the present study suggests that hyperexpression of MCH in hypothalamus of cold-exposed rats participates in the fine tuning of energy expenditure, providing means for optimal heat production with minimal caloric wastage. Apparently, under chronic cold exposure, the role of MCH in the induction of hyperphagia is minimal or absent. These data reinforce the potentiality of MCH as a target for pharmacological therapy of obesity and related diseases, and provide novel support for the concept of dichotomized central control of thermogenesis and food intake.
| Footnotes |
|---|
Abbreviations: AS, With antisense oligonucleotide treatment; BAT, brown adipose tissue; ICV, intracerebroventricular(ly); LH, lateral hypothalamus; MCH, melanin-concentrating hormone; RQ, respiratory quotient; RT, reverse transcription; S, with sense oligonucleotide treatment; T, temperature; UCP, uncoupling protein; VO2, rate of oxygen consumption; VCO2, rate of carbon dioxide production; WO, without oligonucleotide treatment.
Received February 24, 2003.
Accepted for publication July 8, 2003.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Shi, A. D. Strader, S. C. Woods, and R. J. Seeley Sexually dimorphic responses to fat loss after caloric restriction or surgical lipectomy Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E316 - E326. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A Roman, M. Cesquini, G. R Stoppa, J. B Carvalheira, M. A Torsoni, and L. A Velloso Activation of AMPK in rat hypothalamus participates in cold-induced resistance to nutrient-dependent anorexigenic signals J. Physiol., November 1, 2005; 568(3): 993 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pereira-da-Silva, C. T De Souza, A. L Gasparetti, M. J A Saad, and L. A Velloso Melanin-concentrating hormone induces insulin resistance through a mechanism independent of body weight gain J. Endocrinol., July 1, 2005; 186(1): 193 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. A. Unmehopa, J. J. van Heerikhuize, W. Spijkstra, J. W. Woods, A. D. Howard, E. Zycband, S. D. Feighner, D. L. Hreniuk, O. C. Palyha, X.-M. Guan, et al. Increased Melanin Concentrating Hormone Receptor Type I in the Human Hypothalamic Infundibular Nucleus in Cachexia J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2412 - 2419. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Burdakov, O. Gerasimenko, and A. Verkhratsky Physiological Changes in Glucose Differentially Modulate the Excitability of Hypothalamic Melanin-Concentrating Hormone and Orexin Neurons In Situ J. Neurosci., March 2, 2005; 25(9): 2429 - 2433. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |